89bio, INC Schedule 13G passive stakes

Deep Track Capital and its affiliates have reported a complete divestment of their beneficial ownership in 89bio, Inc., holding 0% of common stock as of December 31, 2025.

Pentwater Capital Management LP and Matthew Halbower have reported a complete divestment of their 7.9% stake in 89bio, Inc. as of the filing date.

Deep Track Capital, along with its affiliates, has reported a 6.31% beneficial ownership stake in 89bio, Inc., holding 9,356,171 shares of common stock.

Suvretta Capital Management, LLC and Aaron Cowen have reported a 5.6% beneficial ownership stake in 89bio, Inc. common stock as of September 30, 2025.

Janus Henderson Group plc has filed an amendment to its Schedule 13G, disclosing a reduction in its beneficial ownership in 89bio, Inc. common stock to 3.6%.

Janus Henderson Group PLC has increased its beneficial ownership in 89bio, Inc. to 14.2% of common stock, holding over 20.7 million shares.

The Vanguard Group has reported a passive beneficial ownership of 5.64% of 89bio Inc's common stock, totaling 8,242,154 shares.

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has disclosed a significant 9.18% beneficial ownership stake in biotechnology company 89bio, Inc.

RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 1.3% in 89bio, Inc.'s common stock as of March 31, 2025.

Janus Henderson Group PLC has filed an Amendment No. 6 to its Schedule 13G, disclosing a beneficial ownership of 14.0% in 89BIO, INC. common stock as of March 31, 2025.

Suvretta Capital Management, LLC, along with Averill Master Fund, Ltd. and Aaron Cowen, has filed an amended Schedule 13G disclosing a combined beneficial ownership of 9.9% in 89bio, Inc.'s common stock as of March 31, 2025.

Multiple entities associated with Biotechnology Value Fund, including BVF Partners L.P. and Mark N. Lampert, have collectively reported a beneficial ownership of 3.6% in 89bio, Inc. as of December 31, 2024, through an Amendment No. 4 to their Schedule 13G filing.

Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen have filed an amended Schedule 13G, reporting continued beneficial ownership of 8.5% of 89bio, Inc.'s common stock as of December 31, 2024.

Janus Henderson Group plc, along with its subsidiary Janus Henderson Biotech Innovation Master Fund Ltd, has filed an amended Schedule 13G disclosing a combined beneficial ownership of 15.2% in 89bio, Inc.'s common stock.